ReviewThe Korean journal of parasitology2014
Recent advances in Toxoplasma gondii immunotherapeutics.
Review in The Korean journal of parasitology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Estudo Abrangente do Resveratrol Associado à Sulfadiazina em Linfócitos Infectados com Toxoplasma gondii: Envolvimento da Sinalização Purinérgica na Resposta Imunológica.Acta parasitologica · 2026Article
- Design and immunological evaluation of a multi-epitope vaccine candidate againstFood and waterborne parasitology · 2025Article
- Effective factors in the pathogenesis ofHeliyon · 2024Review
- Metallic Nanoparticles and Core-Shell Nanosystems in the Treatment, Diagnosis, and Prevention of Parasitic Diseases.Pathogens (Basel, Switzerland) · 2023Review
- Nanoparticles as a Delivery System of Antigens for the Development of an Effective Vaccine againstVaccines · 2023Review
- Toxoplasmosis: stages of the protozoan life cycle and risk assessment in humans and animals for an enhanced awareness and an improved socio-economic status.Saudi journal of biological sciences · 2021Review
- A Review on the Prevalence ofInternational journal of environmental research and public health · 2020Review
- Treatment of toxoplasmosis: Current options and future perspectives.Food and waterborne parasitology · 2019Review
- Rhoptry antigens asClinical and experimental vaccine research · 2019Review
- Recent progress in microneme-based vaccines development againstClinical and experimental vaccine research · 2018Review
- Article
- Calcium-dependent protein kinases are potential targets forClinical and experimental vaccine research · 2018Review
- An evaluation of a recombinant multiepitope based antigen for detection of Toxoplasma gondii specific antibodies.BMC infectious diseases · 2017Article
- The genome of the protozoan parasite Cystoisospora suis and a reverse vaccinology approach to identify vaccine candidates.International journal for parasitology · 2017Article
- PREVALENCE OFAfrican journal of infectious diseases · 2017Article
- Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes.Parasite (Paris, France) · 2017Article
- A Systematic Review ofFrontiers in microbiology · 2017Review
- Vaccination against parasites - status quo and the way forward.Porcine health management · 2016Review
- Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.Antimicrobial agents and chemotherapy · 2015Review
- In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasmosis is an opportunistic infection caused by the protozoan parasite Toxoplasma gondii. T. gondii is widespread globally and causes severe diseases in individuals with impaired immune defences as well as congenitally infected infants. The high prevalence rate in some parts of the world such as South America and Africa, coupled with the current drug treatments that trigger hypersensitivity reactions, makes the development of immunotherapeutics intervention a highly important research priority. Immunotherapeutics strategies could either be a vaccine which would confer a pre-emptive immunity to infection, or passive immunization in cases of disease recrudescence or recurrent clinical diseases. As the severity of clinical manifestations is often greater in developing nations, the development of well-tolerated and safe immunotherapeutics becomes not only a scientific pursuit, but a humanitarian enterprise. In the last few years, much progress has been made in vaccine research with new antigens, novel adjuvants, and innovative vaccine delivery such as nanoparticles and antigen encapsulations. A literature search over the past 5 years showed that most experimental studies were focused on DNA vaccination at 52%, followed by protein vaccination which formed 36% of the studies, live attenuated vaccinations at 9%, and heterologous vaccination at 3%; while there were few on passive immunization. Recent progress in studies on vaccination, passive immunization, as well as insights gained from these immunotherapeutics is highlighted in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.